Abstract
Abstract
Background
The PASCAL® transcatheter edge-to-edge repair system (TEER) is established for mitral regurgitation (MR), with the ACE iteration tailored for complex anatomies. Comparative data are limited.
Aims
To compare 3D mitral valve remodeling and procedural outcomes in patients undergoing TEER with PASCAL or PASCAL ACE device at a high-volume tertiary center.
Methods
This retrospective, single-center study included 366 consecutive patients (mean age 77.7 ± 10.2 years; 57.9% male) with moderate-to-severe or severe MR treated between 2019 and 2024. Patients were stratified by device (ACE,
n
= 128, PASCAL,
n
= 238). Procedural outcomes and 3D echocardiographic remodeling were evaluated.
Results
ACE-treated patients had more complex mitral anatomies and larger baseline mitral valve orifice areas (3D-MVOA, 6.55 [5.74–7.96] vs. 5.87 [4.86–7.38] cm
2
;
p
= 0.001). Relative reduction in 3D-MVOA following the first device was similar between groups (ACE − 44.5 ± 6.55% vs. PASCAL − 45.9 ± 6.61%;
p
= 0.066) and consistent across functional, degenerative, and mixed MR subgroups (all
p
> 0.05). ACE cases had a modestly smaller mean pressure gradient increase (+ 1[0–1] vs. + 1[1, 2] mmHg,
p
= 0.046), likely reflecting larger residual MVOAs (3.81 ± 1.11 vs. 3.38 ± 1.07 cm
2
;
p
p
= 0.119). Both devices achieved similarly high procedural success (ACE 100% vs. PASCAL 99.6%,
p
= 1.00) with no procedural complications.
Conclusions
In this real-world cohort, the ACE device was preferentially used in more complex mitral anatomies. Post-procedural MVOA was dictated by baseline valve anatomy rather than device configuration, with comparable relative MVOA reduction, annular remodeling, and procedural success, advocating for an anatomy-guided device selection.